Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá J, Lluch-Rodrigo JA, Pastor-Villalba E.

Vaccine. 2011 Dec 6;29(52):9640-8. doi: 10.1016/j.vaccine.2011.10.038. Epub 2011 Oct 24.

PMID:
22027484
2.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
3.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
4.

The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.

Giglio N, Micone P, Gentile A.

Vaccine. 2011 Sep 14;29 Suppl 3:C35-42. doi: 10.1016/j.vaccine.2011.06.095. Review.

PMID:
21896351
5.

Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.

Dinleyici EC, Yargic ZA.

Expert Rev Vaccines. 2009 Aug;8(8):977-86. doi: 10.1586/erv.09.68. Review.

PMID:
19627181
6.

Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.

Madhi SA, Cohen C, von Gottberg A.

Vaccine. 2012 Sep 7;30 Suppl 3:C21-7. doi: 10.1016/j.vaccine.2012.05.055. Review.

PMID:
22939016
7.

The preventable burden of pneumococcal disease in the developing world.

Scott JA.

Vaccine. 2007 Mar 22;25(13):2398-405. Epub 2006 Sep 18. Review.

PMID:
17028081
8.

Pneumococcal vaccination policy in Europe.

Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P.

Euro Surveill. 2005 Sep;10(9):174-8. Review.

PMID:
16280609
9.

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.

Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR.

Expert Rev Vaccines. 2012 Oct;11(10):1235-47. doi: 10.1586/erv.12.99. Epub 2012 Nov 21. Review.

PMID:
23170992
10.

Adult pneumococcal vaccination guideline. SAMA-SA Pulmonology Society Working Group.

[No authors listed]

S Afr Med J. 1999 Nov;89(11 Suppl):1222-30. Review.

PMID:
10599303
11.

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

van de Vooren K, Duranti S, Curto A, Garattini L.

Pharmacoeconomics. 2014 Jan;32(1):29-45. doi: 10.1007/s40273-013-0113-y. Review.

PMID:
24288207
12.

Effectiveness of 2+1 PCV7 vaccination schedules in children under 2 years: a meta-analysis of impact studies.

Schönberger K, Kirchgässner K, Riedel C, von Kries R.

Vaccine. 2013 Dec 5;31(50):5948-52. doi: 10.1016/j.vaccine.2013.10.042. Epub 2013 Oct 19. Review.

PMID:
24144469
13.

Economic evaluations of pneumococcal vaccination strategies in adults. A summary of the results.

Thiry N, Beutels P, Van Damme P.

Acta Clin Belg. 2005 Nov-Dec;60(6):338-44. Review.

PMID:
16502594
14.

A century of pneumococcal vaccination research in humans.

Grabenstein JD, Klugman KP.

Clin Microbiol Infect. 2012 Oct;18 Suppl 5:15-24. doi: 10.1111/j.1469-0691.2012.03943.x. Epub 2012 Aug 6. Review.

15.

Pneumococcal conjugate vaccines in the prevention of childhood pneumonia.

Ivády B.

Acta Microbiol Immunol Hung. 2010 Mar;57(1):1-13. doi: 10.1556/AMicr.57.2010.1.1. Review.

PMID:
20350875
16.

Bacteremia in feverish children presenting to the emergency department: a retrospective study and literature review.

Bressan S, Berlese P, Mion T, Masiero S, Cavallaro A, Da Dalt L.

Acta Paediatr. 2012 Mar;101(3):271-7. doi: 10.1111/j.1651-2227.2011.02478.x. Epub 2011 Oct 15. Review.

PMID:
21950707
17.

SEPAR-ALAT Consensus Document on Antipneumoccal Vaccination in Smokers.

Jiménez Ruiz CA, Buljubasich D, Sansores R, Riesco Miranda JA, Guerreros Benavides A, Luhning S, Chatkin JM, Zabert G, de Granda Orive JI, Solano Reina S, Casas Herrera A, de Lucas Ramos P.

Arch Bronconeumol. 2015 Jul;51(7):350-4. doi: 10.1016/j.arbres.2014.12.003. Epub 2015 Jan 29. English, Spanish.

18.

Systematic review of pneumococcal disease costs and productivity loss studies in Latin America and the Caribbean.

Bahia L, Toscano CM, Takemoto ML, Araujo DV.

Vaccine. 2013 Jul 2;31 Suppl 3:C33-44. doi: 10.1016/j.vaccine.2013.05.030. Review.

PMID:
23777689
19.

Assessment of vaccine candidates for persons aged 50 and older: a review.

Eilers R, Krabbe PF, van Essen TG, Suijkerbuijk A, van Lier A, de Melker HE.

BMC Geriatr. 2013 Apr 15;13:32. doi: 10.1186/1471-2318-13-32. Review.

20.

Financing vaccinations - the South African experience.

Blecher MS, Meheus F, Kollipara A, Hecht R, Cameron NA, Pillay Y, Hanna L.

Vaccine. 2012 Sep 7;30 Suppl 3:C79-86. doi: 10.1016/j.vaccine.2012.04.042. Review.

PMID:
22939027
Items per page

Supplemental Content

Write to the Help Desk